COMP <GO>
TVTX vs JNJ // NET PROFIT MARGIN
Travere Therapeutics Inc. (NASDAQ) VS. Johnson & Johnson (NYSE) • 15-METRIC TALLY: TVTX 3
— JNJ 8
▲ NET PROFIT MARGIN LEADER: JNJ
LAST: $50.39 (-0.36%) • MKT CAP: $4.77B
net-margins
-5.20%
LAST: $273.20 (-0.73%) • MKT CAP: $662.49B
net-margins
28.50%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (TVTX VS. JNJ)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | TVTX | JNJ | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 96.00% | 67.90% | +28.10 | TVTX | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -13.00% | 25.50% | -38.50 | JNJ | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | 18.5x | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | 0.33% | 2.97% | -2.64 | JNJ | /fcf-yield <GO> |
| Operating Margin | -12.80% | 34.70% | -47.50 | JNJ | /operating-margins <GO> |
| Net Profit Margin ACTIVE | -5.20% | 28.50% | -33.70 | JNJ | /net-margins <GO> |
| Revenue Growth (YoY) | 110.50% | 6.00% | +104.50 | TVTX | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 3.44 | 5.59 | -2.15 | JNJ | /balance-sheet <GO> |
| Piotroski F-Score Quality | 7/9 | 8/9 | -1.00 | JNJ | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | 7.20% | 7.20% | 0.00 | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 35.4 | 60.4 | -24.91 | JNJ | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 1.08 | 1.08 | 0.00 | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | 18.0x | 23.0x | -5.00 | TVTX | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $4.77B | $662.49B | -$657.73B | JNJ | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | TVTX REV | JNJ REV | TVTX GROSS % | JNJ GROSS % | TVTX FCF | JNJ FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $490.7M | $94.19B | 97.9% | 67.9% | $15.7M | $19.70B |
| FY 2024 | $233.2M | $88.82B | 96.7% | 69.1% | -$248.0M | $19.84B |
| FY 2023 | $145.2M | $85.16B | 44.0% | 44.0% | -$286.6M | $18.96B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
TVTX // BETA 1.08
JNJ // BETA 1.08